CHANEL ZELAYA: Open Payments
NPI 1700507761 · ARLINGTON, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$896 in 23 payments from 10 companies in 2025. Trend: 2023 $522 · 2024 $1,771 · 2025 $896
Food & beverage: $896
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $213 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $158 |
| Otsuka America Pharmaceutical, Inc. | 2 | $146 |
| Vanda Pharmaceuticals Inc. | 1 | $122 |
| Braeburn Inc. | 1 | $109 |
| Tris Pharma Inc | 2 | $44 |
| Supernus Pharmaceuticals, Inc. | 2 | $36 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Bausch Health US, LLC | 1 | $25 |
| Vertical Pharmaceuticals, LLC | 1 | $14 |
Products named: VRAYLAR, CAPLYTA, REXULTI, FANAPT, BRIXADI, Dyanavel XR, Qelbree, Auvelity.
Industry payments across VA — which companies pay providers there.
